Sodium-glucose cotransporter-2 inhibitors are now considered second-line treatment agents for type 2 diabetes and offer a unique treatment approach with added cardiorenal benefits. Drugs in this class increase the risk of euglycemic diabetic ketoacidosis, which may be difficult to diagnose if clinicians are not aware of the risk factors and subtle symptoms. This article describes a case of euglycemic diabetic ketoacidosis in a patient with coronary artery disease who was taking a sodium-glucose cotransporter-2 inhibitor and experienced acute mental status changes immediately after heart catheterization.
Skip Nav Destination
Symposium: Diabetes Case Reports| March 15 2023
Euglycemic Diabetic Ketoacidosis Associated With SGLT2 Inhibitor Therapy: A Case Report
CE Article Video This article has one or more videos
Gwen Klinkner, DNP, RN, BC-ADM, CDCES, FADCES;
Maggie Steingraber-Pharr, MSN, RN, FNP-BC
AACN Adv Crit Care (2023) 34 (1): 27–32.
Gwen Klinkner, Maggie Steingraber-Pharr; Euglycemic Diabetic Ketoacidosis Associated With SGLT2 Inhibitor Therapy: A Case Report. AACN Adv Crit Care 15 March 2023; 34 (1): 27–32. doi: https://doi.org/10.4037/aacnacc2023830
Download citation file:
Don't already have an account? Register